Mustonen, Tiina <br/><br/>
Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.  [electronic resource] 

 -  Multiple sclerosis and related disorders  Feb 2020 
 - 101498 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2211-0356 
<br/><br/><label>Standard No.: </label>10.1016/j.msard.2019.101498  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenal Cortex Hormones--administration & dosage<br/>Adult<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Natalizumab--administration & dosage<br/>Retrospective Studies<br/>Risk Factors<br/>Secondary Prevention<br/>Severity of Illness Index<br/>Symptom Flare Up<br/>Time Factors<br/>Young Adult